Epirubicin in combination with the taxanes.

@article{Trudeau2001EpirubicinIC,
  title={Epirubicin in combination with the taxanes.},
  author={M E Trudeau and Olivia Pagani},
  journal={Seminars in oncology},
  year={2001},
  volume={28 4 Suppl 12},
  pages={41-50}
}
The anthracyclines, and doxorubicin in particular, have been the most widely used drugs for advanced and metastatic breast cancer. Epirubicin shares the same spectrum of antitumor activity as doxorubicin, however, a therapeutic advantage of epirubicin is the higher cumulative dose at which the anthracycline-induced cardiotoxicity becomes clinically evident. The taxanes have quickly been established as important chemotherapeutic agents in the armamentarium of drugs to treat breast cancer… CONTINUE READING